Drug therapy.
D000661:Amphetamine / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D002749:Chlorprothixene / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006213:Hallucinogens / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008094:Lithium / Q000627:therapeutic use; D008238:Lysergic Acid Diethylamide / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy*; D010640:Phenothiazines / Q000627:therapeutic use; D011346:Prochlorperazine / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy; D012110:Reserpine / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D013881:Thioridazine / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use
D000928:Antidepressive Agents; D006213:Hallucinogens; D006993:Hypnotics and Sedatives; D010640:Phenothiazines; D014149:Tranquilizing Agents; D012110:Reserpine; D008238:Lysergic Acid Diethylamide; D008094:Lithium; D002749:Chlorprothixene; D000661:Amphetamine; D006220:Haloperidol; D013881:Thioridazine; D002746:Chlorpromazine; D011346:Prochlorperazine